CLGL, AAPH, AMPE are included in our Top Penny Stock Gainers
CLGL, AAPH, AMPE are active stocks in the news today.
Dallas, TX 3/19/2012 10:14 PM GMT (WooEB)
California Gold Corp. (OTC BB: CLGL) reached up 66% in morning trading to $.083 with 900K shares traded. California Gold Corp. is an early stage U.S. public company pursuing a mineral exploration strategy in the metals mining sector in the Americas, with an initial focus on identifying and acquiring rare and precious metals mining opportunities for development and production. California Gold Corp. (OTC BB: CLGL) Friday announced it is scheduling an April 2012 start for an exploration drilling program at the Company's AuroTellurio Project, located in the La Bambolla gold-tellurium mining district near Moctezuma, Sonora, Mexico, near the northern city of Hermosillo. Six core holes will be drilled as part of this initial drilling program involving a total of 3,000 meters of diamond drilling. Geologic work, supplemented by two geophysical surveys, has delineated three drilling targets within California Gold's mining concessions.
American Petro-Hunter, Inc. (OTCBB: AAPH) reached up 14.29% in morning trading to $.40 with 900K shares traded. American Petro-Hunter, Inc. is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County, Kansas and at its North Oklahoma Project area. American Petro-Hunter, Inc. (OTC.BB: AAPH.OB - News) announced that the NOM-3H horizontal oil and gas well has begun commercial oil and gas sales. The well has shipped an inaugural 1,000 barrels following the first weeks of production.
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) reached up 34.54% in morning trading to $3.61 with 650K shares traded. Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE - News) today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at email@example.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE